Susanne Hewitt, MD
Ophthalmology · Roswell, GANPI 1396748513
Payments from drug & device makers
Across 186 payments — averaging $48.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$1K
- Glaukos Corporation$1K
- AbbVie$882
- Johnson & Johnson Surgical Vision, Inc.$832
- Alcon$686
- Sight Sciences, Inc.$607
- plus $4K from 21 others
Across 1 payment — averaging $48.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk$48
What the payments were for
- Consulting fees$1502%
- Travel & lodging$8269%
- Food & beverage$8,06989%
- Education$180%
- Gifts$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 4 | $1,351 |
| Glaukos Corporation | 13 | $1,089 |
| AbbVie(2 entities) | 41 | $882 |
| Johnson & Johnson Surgical Vision, Inc. | 19 | $832 |
| Alcon | 11 | $686 |
| Sight Sciences, Inc. | 22 | $607 |
| Ivantis, Inc | 7 | $563 |
| Oyster Point Pharma, Inc. | 11 | $395 |
| Bausch & Lomb Americas Inc. | 9 | $303 |
| Amgen(2 entities) | 4 | $283 |
| Genentech USA, Inc. | 2 | $258 |
| Eyepoint US, Inc. | 2 | $250 |
| Sun Pharmaceutical Industries Inc. | 7 | $222 |
| Mallinckrodt Hospital Products Inc. | 3 | $190 |
| Rxsight Inc | 3 | $175 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $148 |
| Biotissue Holdings Inc. | 7 | $138 |
| Alimera Sciences, Inc. | 1 | $127 |
| Regeneron Healthcare Solutions, Inc. | 1 | $121 |
| Dompe US, Inc. | 5 | $116 |
| Astellas Pharma US Inc | 1 | $105 |
| Harrow Eye, LLC | 3 | $97 |
| Aerie Pharmaceuticals, Inc. | 3 | $66 |
| Akorn, Inc. | 1 | $38 |
| Shire North American Group Inc | 1 | $30 |
| NEW World Medical,inc. | 1 | $22 |
| Ocular Therapeutix, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$530
- OMNI(R) SURGICAL SYSTEM (US)$296
- TYRVAYA$264
- Hydrus Microstent$262
- VABYSMO$258
- DEXYCU$250
- TEPEZZA$228
- Tecnis IOL$227
- iStent inject W$183
- iStent Trabecular Micro-Bypass System Model iS3$160
- Hydrus$150
- enVista MX60 IOL$138
- Iluvien$127
- ACTHAR$126
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$125
- Tecnis 1-piece IOL$122
- EYLEA$121
- ENVISTA TORIC$114
- Tecnis Simplicity$107
- Izervay$105
How this compares
$9,107 in reported general payments places this provider in the 80th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 109 | $109,603 |
| LumiganBimatoprost | 64 | $39,429 |
| Cyclosporine | 60 | $28,540 |
| XiidraLifitegrast | 23 | $26,099 |
| RocklatanNetarsudil Mesylat/Latanoprost | 36 | $25,162 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $10,897 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 31 | $7,049 |
| Brimonidine Tartrate | 93 | $5,850 |
| Prednisolone Acetate | 204 | $5,583 |
| Latanoprost | 430 | $5,017 |
| ProlensaBromfenac Sodium | 14 | $4,928 |
| Timolol Maleate | 143 | $4,342 |
| Travoprost | 23 | $4,047 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $3,078 |
| Loteprednol Etabonate | 22 | $2,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $882 | $159,928197 claims |
| Bausch & Lomb Americas Inc.Xiidra | $303 | $26,09923 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $66 | $25,16236 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $148 | $7,09536 claims |
| AlconSimbrinza | $686 | $3,07813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Roswell
- Larry HeitRoswell$25K
- Dennis MarcusAugusta$9.2M
- Robert StoltzMarietta$3.9M
- Eugene McLaurinSavannah$3.3M
- Clayton BlehmGainesville$1.7M
- Lakshmana KooragayalaMarietta$1.4M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.